Most private-company fundamentals had not materially changed even though public multiples were collapsing.

A private company's product or revenue may not change overnight, but the financing environment, hiring assumptions, exit paths, and acceptable burn absolutely can. Those changes matter enough that the distinction becomes too comforting.

The first and second derivative of the 10-year yield is the best practical signal for when the market can stabilize.

Rates were central to the repricing, so the 10-year was an important barometer. But it was not the only one; liquidity, earnings durability, and private financing sentiment mattered too.

The Fed's communication shift was a major immediate driver of the markdown in growth stocks.

The timing and content of the statement-plus-minutes sequence support that interpretation. The market was repricing duration risk and expected policy tightening at the same time.

High-growth public stocks had already taken the bulk of the hit by early January 2022.

Many growth names had already fallen sharply, but the idea that the bulk of the pain was over proved too optimistic in hindsight. The better version is that they moved first, not that they were close to done.

Many 2015-2021 vintage unicorns were marked at levels they could not realistically defend in public markets.

That was a central feature of the later correction. The public comp reset exposed how many late-stage private marks depended on an exit environment that no longer existed.

Investors and fund managers have a strong incentive to delay or resist markdowns on large private positions.

Write-downs hurt reported performance, fundraising optics, and internal narratives. That creates an obvious temptation to wait for the market to bail out old marks.

Most startups that raised at extreme valuations did not really have the multi-year runway optimists were assuming.

The precise '18 months or less' line is too specific to validate generically, but the broader warning that effective runway was shorter than it looked is sound.

The market would force much faster spending discipline than many startup teams initially expected.

That is exactly what later happened across the market. Boards and founders had to shift from growth-first planning to burn control and survival math.

If a startup raised enough money at a very high valuation, it largely removed downside and can simply grow into the mark.

The cash buys time, but it does not remove the valuation overhang, the fundraising optics, or the organizational habits built for a different market. In many cases it postpones rather than removes the problem.

Companies can preserve the benefits of a giant up-round by quietly adjusting spend without a more disruptive reset.

Some companies can do that, especially if gross margins and product-market fit are strong. But many cannot cut deeply enough without changing strategy, headcount, or growth expectations more visibly.

A few lower-priced high-profile deals can reset private-market valuation expectations much faster than general commentary can.

Markets often need visible clearing prices to replace denial with a new consensus. Once those prints arrive, the narrative changes quickly.

The trickle-down effect from public repricing into private financing was inevitable even if it had not fully arrived yet.

Private pricing could lag, but it could not stay detached indefinitely from public comps, exit windows, and the cost of capital.

Very high entry valuations create unhealthy incentives for both management and investors if the company cannot quickly justify them.

That pressure can push teams toward overspending, overpromising, or delaying hard resets. It also makes future financings and exits more structurally awkward.

A down market can turn a superficially impressive round into a strategic liability rather than a pure win.

The company gets the cash, but it may also inherit a valuation it cannot defend, a cap table it cannot easily advance, and a culture still sized for the old market.

Social proof and secondhand diligence, not original technical analysis, were central to how Theranos kept raising money and winning credibility.

The company repeatedly benefited from famous names, glowing coverage, and partner logos that signaled legitimacy. That pattern fits Chamath's argument well.

Top-tier venture firms mostly stayed away because Holmes would not survive real diligence.

That is directionally plausible and consistent with the episode's discussion, but Chamath states it more absolutely than the verified public record supports. The stronger claim is that stronger technical diligence would have made the story harder to sustain.

The key red line for founders is lying about the present state of the business rather than failing to deliver a long-term vision.

That is the clearest legal and ethical distinction in the case. Startup optimism is not the same thing as misrepresenting existing product performance, customers, or validation.

The Holmes case is not especially representative of serious Silicon Valley venture investing.

Many sophisticated venture firms did stay away, which supports Sacks's point. But the broader Valley environment still rewarded story-first social proof, celebrity boards, and hype cycles that made the fraud easier to scale.

Positive press materially reinforced Holmes's exaggerations and helped unlock capital, employees, and partnerships.

High-profile media attention made Theranos look inevitable and important. That kind of reputational lift clearly mattered for recruiting, fundraising, and business development.

A claim as extraordinary as hundreds of tests from a tiny blood sample deserved much more skeptical coverage much earlier.

The claim carried an unusually high burden of proof because it challenged basic industry practice in a regulated medical setting. The incentives of narrative journalism were a poor fit for that burden.

Once a venture GP reaches sufficient scale, an IPO becomes the most rational way to crystallize management-company value.

The economic case is strong, but rationality depends on control preferences, regulation, cultural costs, and whether the founders value staying private more than immediate monetization.

The more a giant venture firm behaves like a diversified allocator, the less pure carry economics explain its value.

At scale, platform, brand, distribution, and management-fee durability start to matter much more. That does make the business easier to compare with alternative-asset managers.

Historically, many venture firms were not treated as separately monetizable enterprises in the way a public market might treat a scaled manager.

That traditional venture norm is well described by Sacks and fits the older partnership model, where the real economics sat in the funds and carry rather than in a separately traded GP.

Public ownership would materially change partner incentives by making future partners more like compensated employees than true owners.

A public cap table, public board, and public-market compensation system would inevitably reduce the old one-share-of-the-franchise dynamic that makes a private partnership distinctive.

A few giant firms were on track to control a very large share of private growth capital.

The broad concentration trend was real, even if his exact market-share rhetoric was more directional than statistical. Large diversified franchises kept taking a bigger share of the financing stack.

At sufficient scale, a top venture firm starts to resemble an asset-management company more than a traditional venture partnership.

Once a firm spans many funds, stages, and support functions, the business increasingly includes management-company economics and platform effects beyond classic carry from a few flagship funds.